MSD and Pfizer were 2018’s top gainers on the Dow Jones Industrial Average for the calendar year, with both companies bucking the trend of an otherwise lacklustre year for the index.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.